| Name | Title | Contact Details |
|---|
digiChart Announces New Executives and New Offices July 15, 2010 BRENTWOOD, Tenn.--(BUSINESS WIRE)--digiChart, Inc. today announced the appointment of two new members to its executive team, Bob Allen and Stephen Faris. The company also announced the relocation of its headquarters to Brentwood, TN, a nearby suburb of Nashville, TN. Bob Allen joins digiChart as National Director of Sales. Mr. Allen will be responsible for all the sales and marketing efforts of the company. Most recently, he served as Vice President of Sales in McKessons Physician Practice Solutions business. He brings over 20 years experience in sales and healthcare technology. Stephen Faris will serve as Vice President of Technology, leading digiCharts product development and technical operations. He previously served as Chief Technology Officer for Healthgate Data Corporation and has extensive experience consulting with companies on their technology and applications strategies. We are excited two exceptional leaders such as Bob and Stephen join our executive team, said digiChart CEO Bill Bates. We are growing and moving forward with exciting initiatives to fully connect OB-GYN care. Bob and Stephens experience will serve us well. They will be central to our success. digiChart also announced the relocation of its headquarters to Brentwood, TN, a nearby suburb of Nashville, TN. The move positions the leader in OB-GYN electronic medical records and practice management systems software for its growth plans and will enable improved service and support for its customers throughout the United States. The Nashville area is a hub for the healthcare, said COO Shelley Predmore. We have enjoyed a rewarding history of growth and success from being in the center of the industrys activities and will continue to do so. Our new offices offer us a state-of-the-art training center for our clients and better consolidate our overall operations. The space will serve us for years to come as we serve our customers. The companys new address is: digiChart, Inc. 100 Winner's Circle, Suite 450 Brentwood, TN 37027 About digiChart, Inc. (www.digichart.com) Based in Brentwood, TN, digiChart, Inc. is a leader in healthcare information technology solutions and services. Dedicated to improving women's healthcare, digiChart provides electronic health record (EHR) and practice management system (PMS) solutions, along with the related training, implementation and workflow improvement services. OB-GYN practices across the country use digiChart's solutions to streamline and optimize their practices clinically and inancially, as well as achieve higher rates of patient satisfaction. Every day, over 100,000 active pregnancies and nearly 1,800,000 womens records are managed through digiCharts solutions. digiChart is a MedCare company. MedCare is a althcare-focused fund invested in a portfolio of healthcare services, healthcare IT and medical device companies with combined revenues of over $350M. Contacts digiChart, Inc. Shelley Predmore, Chief Operating Officer, 615-312-1630 ore@digichart.com
Applied Cardiac Systems Inc is a Laguna Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Endocare is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Endocare is based in Irvine, CA. You can find more information on Endocare at www.endocare.com
Cord:Use is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Orlando, FL. To find more information about Cord:Use, please visit www.corduse.com
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.